Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$126.75-0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INCY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks INCY against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive growth in total net sales including Jakafi, Opzelura, and Hematology and Oncology portfolio products such as Niktimvo, Monjuvi/Minjuvi, and Zynyz.
Stated as a priority in 6 of last 6 quarters. Total revenue grew from $1.27 billion in 2026-Q1 to $1.67 billion in 2026-Q2 (+38%), with total net sales increasing 40% year-over-year in 2026-Q2. Hematology and Oncology net sales guidance was raised to $860 - $890 million for 2026. Management is delivering broad-based growth across marketed products consistent with stated priorities.
“Our second quarter was marked by broad-based sales growth... Every marketed product contributed to growth...”
“Our first quarter represented a strong start to 2026, driven by 20% year-over-year net sales growth and strong commercial execution.”
“Our fourth quarter and full year 2025 results reflect exceptional core business growth and pipeline progress.”
“Our third-quarter results demonstrate strong growth across our product portfolio, with net product revenues increasing 19% year-over-year.”
“Our second quarter results reflect strong growth for Jakafi, Opzelura and Niktimvo, positioning us well to deliver on our 2025 objectives.”
“The double-digit revenue growth in the first quarter driven by the continued growth of Jakafi and Opzelura and the recent launch of Niktimvo.”
Control research and development and selling, general and administrative expenses while investing in late-stage pipeline and new product launches.
Stated as a priority in 6 of last 6 quarters. GAAP R&D expenses were $515.9M in 2026-Q1 and $517.0M in 2026-Q2, with SG&A expenses rising from $328.1M to $351.7M. Full year 2026 GAAP R&D and SG&A expense guidance was raised to $4.915 - $4.995 billion. Management is maintaining investment in pipeline and launches while managing expense growth.
“GAAP and non-GAAP R&D expenses were $517.0 million and $478.8 million, an increase of 4% and 5%, respectively.”
Progress multiple Phase 3 clinical trials across hematology, oncology, and inflammation indications with anticipated data readouts and regulatory submissions.
Stated as a priority in 6 of last 6 quarters. Management highlights 10 Phase 3 studies underway in 2026 including INCA033989, INCB161734, INCA33890, and INCB123667, with multiple data readouts and regulatory submissions anticipated. The pipeline progression is consistent with management's stated focus on advancing late-stage assets.
Finalize acquisition of Vega Therapeutics and integrate latarcibart into the pipeline for von Willebrand disease treatment development.
Stated as a priority in 2 of last 6 quarters. The acquisition of Vega Therapeutics was completed in 2026-Q2 for $1.25 billion, adding latarcibart to the pipeline. Management expects an IPR&D expense of approximately $1.27 billion in 2026 related to this transaction. The acquisition is complete and integration is underway as planned.
“Completed acquisition of Vega Therapeutics, adding latarcibart to late-stage pipeline.”
Obtain regulatory approvals and launch products including Jakafi XR, Opzelura in Europe, Monjuvi/Minjuvi, Zynyz, and povorcitinib indications.
Stated as a priority in 6 of last 6 quarters. Management expects regulatory decisions for Jakafi XR mid-2026, Opzelura EU approval in Q3 2026, Monjuvi/Minjuvi US approval in early 2027, and povorcitinib NDA acceptance in early 2026 with potential approvals late 2026/early 2027. Recent approvals include Niktimvo and Zynyz. The trajectory shows ongoing regulatory progress and launches.
Over the trailing year it converted 1.20x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“GAAP and non-GAAP R&D expenses were $515.9 million and $476.7 million, an increase of 18% and 19%, respectively.”
“GAAP and non-GAAP R&D expenses were $611.4 million and $575.2 million, an increase of 31% and 37%, respectively.”
“GAAP and non-GAAP R&D expenses were $506.6 million and $467.0 million, a decrease of 12% and 11%, respectively.”
“GAAP and Non-GAAP research and development expenses for the quarter ended June 30, 2025 decreased 57% and 58%, respectively.”
“GAAP and Non-GAAP research and development expense for the quarter ended March 31, 2025 increased 2% and 3%, respectively.”
“Ten clinical data readouts, including data from four registrational trials, expected throughout the second half of 2026.”
“Late-stage pipeline with 10 Phase 3 studies underway, including initiation of a Phase 3 trial evaluating INCB161734 in pancreatic ductal adenocarcinoma.”
“By the end of the year, we expect to have fourteen pivotal clinical trials underway.”
“We are actively reviewing our R&D efforts and focusing on high-value programs that are scientifically differentiated.”
“Phase 1 data for INCA033989 and JAK2V617Fi anticipated in 2025; Phase 3 trial evaluating axatilimab in chronic GVHD ongoing.”
“Phase 1 studies evaluating mutCALR and JAK2V617Fi enrolling patients; Phase 2 trial evaluating axatilimab ongoing.”
“Acquisition of Vega Therapeutics expected to impact 2026 financial results including IPR&D expense.”
“Jakafi XR expected regulatory decision and potential launch mid-2026.”
“Opzelura cream positive CHMP opinion; regulatory decision expected Q3 2026.”
“Monjuvi/Minjuvi global regulatory submissions accepted Q2 2026; potential US approval Q1 2027.”
“Povorcitinib NDA submission accepted by FDA in Q1 2026; potential approval late 2026/early 2027.”
“Zynyz approved by FDA for SCAC; EMA positive opinion received.”
“Niktimvo approved by FDA for chronic GVHD.”